These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 27543821

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation.
    Li H, Guo Z, Si T, Wang H.
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):620-7. PubMed ID: 23325276
    [Abstract] [Full Text] [Related]

  • 24. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial.
    Letzen BS, Malpani R, Miszczuk M, de Ruiter QMB, Petty CW, Rexha I, Nezami N, Laage-Gaupp F, Lin M, Schlachter TR, Chapiro J.
    Clin Imaging; 2021 Oct; 78():194-200. PubMed ID: 34022765
    [Abstract] [Full Text] [Related]

  • 25. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.
    Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, Han KH, Kim SU, Kim MJ.
    Eur J Cancer; 2013 Mar; 49(4):826-34. PubMed ID: 22995582
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response.
    Dioguardi Burgio M, Sartoris R, Libotean C, Zappa M, Sibert A, Vilgrain V, Ronot M.
    Cancer Imaging; 2019 Nov 15; 19(1):75. PubMed ID: 31730491
    [Abstract] [Full Text] [Related]

  • 30. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.
    Tacher V, Lin M, Duran R, Yarmohammadi H, Lee H, Chapiro J, Chao M, Wang Z, Frangakis C, Sohn JH, Maltenfort MG, Pawlik T, Geschwind JF.
    Radiology; 2016 Jan 15; 278(1):275-84. PubMed ID: 26131913
    [Abstract] [Full Text] [Related]

  • 31. The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation?
    Liu Q, Li A, Sun S, Luo R, Chen F.
    J BUON; 2014 Jan 15; 19(2):398-405. PubMed ID: 24965398
    [Abstract] [Full Text] [Related]

  • 32. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, Suh SJ, Lee BJ, Seo YS, Yim HJ, Seo TS, Lee CH, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS.
    J Hepatol; 2013 Jun 15; 58(6):1181-7. PubMed ID: 23395691
    [Abstract] [Full Text] [Related]

  • 33. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602.
    Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, Osuga K, Takahashi M, Arai Y, Japan Interventional Radiology in Oncology Study Group-JIVROSG.
    Ups J Med Sci; 2013 Mar 15; 118(1):16-22. PubMed ID: 23167460
    [Abstract] [Full Text] [Related]

  • 34. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?
    Sahu S, Schernthaner R, Ardon R, Chapiro J, Zhao Y, Sohn JH, Fleckenstein F, Lin M, Geschwind JF, Duran R.
    Radiology; 2017 Jun 15; 283(3):883-894. PubMed ID: 27831830
    [Abstract] [Full Text] [Related]

  • 35. Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience.
    Favelier S, Boulin M, Hamza S, Cercueil JP, Cherblanc V, Lepage C, Hillon P, Chauffert B, Krausé D, Guiu B.
    Cardiovasc Intervent Radiol; 2013 Aug 15; 36(4):1039-46. PubMed ID: 23224215
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma.
    Hyun D, Shin SW, Cho SK, Park KB, Park HS, Choo SW, Do YS, Choo IW, Shin JW, Lim SJ.
    Acta Radiol; 2015 Dec 15; 56(12):1437-45. PubMed ID: 25480473
    [Abstract] [Full Text] [Related]

  • 37. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.
    Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R, Wang E, Baker T, Abecassis M, Benson AB, Nemcek AA, Omary R, Salem R.
    JAMA; 2010 Mar 17; 303(11):1062-9. PubMed ID: 20233824
    [Abstract] [Full Text] [Related]

  • 38. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
    Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E, Eng J, Kamel IR.
    Radiology; 2013 Aug 17; 268(2):431-9. PubMed ID: 23616632
    [Abstract] [Full Text] [Related]

  • 39. Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma.
    Donati OF, Do RK, Hötker AM, Katz SS, Zheng J, Moskowitz CS, Beattie C, Brown KT.
    Eur Radiol; 2015 Sep 17; 25(9):2779-88. PubMed ID: 25850892
    [Abstract] [Full Text] [Related]

  • 40. Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma.
    Shim JH, Lee HC, Won HJ, Shin YM, Kim KM, Lim YS, Suh DJ.
    J Hepatol; 2012 Feb 17; 56(2):406-11. PubMed ID: 21782761
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.